New Platform Addresses Integration and Silo Challenges
With the average clinical trial using of 5-7 different clinical systems, one of the critical business challenges the industry faces today is turning these siloes of data into operational intelligence
"With the average clinical trial using of 5-7 different clinical systems, one of the critical business challenges the industry faces today is turning these siloes of data into operational intelligence," said Peg Regan, President & CEO of eClinical Insights. To address this issue, eClinical Insights, a provider of cloud-based clinical trials software, announced the launch of its eClinical Intelligence Platform.
The platform delivers real-time clinical trial intelligence and workflow capabilities through a suite of cloud-based applications, which acquires and integrates data from any clinical system, and is powered by a business analytics engine. The platform is based on an open architecture and includes a library of out-of-the-box interfaces to leading EDC technologies, enabling customers to leverage existing technology investments as integrated components of the eClinical Insights platform. Delivered through a Software-as-a-Service (SaaS) subscription model, the platform includes a suite of cloud-based trial management applications that are available on per study basis, and can be turned on and off as needed, on both new and ongoing trials.
You can read the full release here.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
